Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 3/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25204691 | 1.00 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Oxirane SCHEMBL27942127 | 0.94 | CA2 (0.41) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL19744390 | 0.78 | MAOB (0.45) | NISCHMAOAMAOB | |
| SCHEMBL29462397 | 0.78 | CA2 (0.46) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6593801 | 0.75 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8638651 | 0.75 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL460126 | 0.75 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL155647 | 0.75 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL3230349 | 0.75 | HTR1A (0.45) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1567113 | 0.75 | HTR1A (0.45) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-11505545-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-22 | — | — | US | disclosed |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CA2 4715/4885HTR1A 3631/4885SIGMAR1 2852/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | CA2 3671/4885HTR1A 3237/4885SIGMAR1 4524/4885 |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | CA2 2135/4885HTR1A 3640/4885SIGMAR1 4133/4885 |
| US-11505545-B2 | Anthelmintic quinoline-3-carboxamide derivatives | HRH4, HRH2, H1-5 | CA2 1271/4885HTR1A 892/4885SIGMAR1 1105/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | CA2 2135/4885HTR1A 3640/4885SIGMAR1 4133/4885 |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | CA2 2135/4885HTR1A 3640/4885SIGMAR1 4133/4885 |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | EZH2, BMI1, EZH1 | CA2 3736/4885HTR1A 4332/4885SIGMAR1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.